Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

2019349 citationsJournal Articlegreen Open Access

Authors

Osimertinib demonstrated favorable activity with manageable toxicity in patients with NSCLC harboring uncommon EGFR mutations.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 38, Issue 5, pp. 488-495

Field-Weighted Citation Impact: 32.78